NCT02945826

uPAR-PET/MRI in Glioblastoma Multiforme

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of glioblastoma.

Detailed description

68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR), which is a promising imaging biomarker of tumor aggressiveness. 68Ga-NOTA-AE105 PET/MRI will be applied in patients suspected of glioblastoma multiforme. The uptake of the radioligand 68Ga-NOTA-AE105 will be compared and correlated with expression of the molecular target: uPAR using immunohistochemistry of tumor tissue samples obtained during routine stereotactic biopsies or operation. In addition, the semiquantitative uptake (standard uptake values, SUVs) of 68Ga-NOTA-AE105 in tumor tissue will be correlated with overall survival and progression free survival

Conditions

• Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	One injection of 68Ga-NOTA-AE105	One injection of 68Ga-NOTA-AE105
DEVICE	PET/MRI	Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain

Timeline

• Start date: 2017-01-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2016-10-26
• Last updated: 2018-04-10

Locations

1 site across 1 country: Denmark